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ABSTRACT 
Background: Diabetes caused by insulin production disturbance is considered as the most common metabolic 
disorder all over the world. Diabetes may outbreak because of low insulin secretion by Islets of Langerhans β-
cells, insulin resistance or both of them. In this way, using stem cells, which have the capability to 
differentiate into pancreatic β-cells, is one of novel methods in this field. MSCs are the most important 
candidates for cellular therapy. 
Materials and Methods: Insulin level was examined using ELIZA method. In order to examine the 
morphology of differentiated cells, they were stained by Dithizone. Insulin-producer cells are cells which turn 
into red as a result of staining. Specific gene involving insulin-producing cells was evaluated by Real Time-PCR 
method. 
Results: The ELISA results showed that the treated cells secreted more insulin than the control group. 
Moreover, we found differentiation of MSCs toward insulin-secreting cells. In order to evaluate insulin 
production in clusters on day 21 of differentiation, we used dithizone (DTZ) staining. PDX-1 gene was 
confirmed by RT- PCR analysis. 
Conclusion: In this study, we differentiated MSCs into insulin-producing cells in vitro. It is concluded that 
MSCs may be considered as an excellent candidate in β-cell therapy in diabetes patients. 
 




   Diabetes, caused by insulin production 
disturbance, is considered as the most common 
metabolic disorder all over the world. Diabetes may 
outbreak because of low insulin secretion by Islets 
of Langerhans β-cells, insulin resistance or both of 
them1. Currently more than 387 million people 
suffer from diabetes mellitus around the world. 
According to estimates, this figure will reach 500 
million people by 2030. Generally, diabetes is 
divided into two types: Type I is a disorder which 
caused by auto immune destruction of  Pancreas β-
cells  , and in Type II diabetes caused mainly 
because of progressive body resistance against 
insulin which results in β-cells destruction and 
insufficient insulin production.2  
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Although the exact source of this disorder is 
unknown, there are some evidence which reveal 
that genetic and environmental factors affect the 
process of auto immune excitation3-5. On the other 
hand, no conclusive treatment has been found for 
diabetes, while taking oral drugs and insulin 
injection are among common treatments. Also, 
Pancreas transplantation and Islets langerhans cells 
are also practiced. But, Pancreas transplantation is 
limited because of Diabetes spread and limited 
number of donors.  
In this way, using stem cells, which have the 
capability to differentiate into Pancreas β-cells, is 
one of novel methods in this field6. MSCs are the 
most important candidates for cellular therapy. 
There is fundamental indication from in vitro7, 
preclinical 8-10 and clinical 11-14 studies. Stem cells are 
unspecialized cells with high proliferation and have 
the following characteristics: regeneration, 
differentiation, self-renewal 15 if induced by a 
specific driver. Stem cells can divide several times 
and maintain multipotency, and can differentiate 
into specialized cells 16. 
There are two kinds of stem cells in the bone 
marrow: 1) hematopoietic stem cells, and 2) 
Mesenchymal Stem Cells (MSCs), which 
differentiation into fat cells, cartilage and bone in 
specific circumstances17. Meanwhile genesis, 
Pancreas produces factors which cause all stem 
cells to differentiate into insulin-producer cells 18. 
MSCs express surface indices MHC-I , CD25 , CD44 , 
CD73 , CD90 , CD105 , CD166 and is negative in 
terms of surface markers MHC-II , CD14, CD31 , 
CD34 , CD45,HLA-DR.  Three main conditions for 
approving the identity of mesenchymal are: 1) in 
the culture, cell adherence to flask bottom, 2) 
expression of some markers and lacking expression 
of other markers, and 3) the capability to 
differentiate into fat, bone and cartilage cells.  
Given that providing MSCs from bone marrow is 
laborious, and in some cases observing ethical 
codes isn’t possible, researchers are looking for 
alternative resources, including umbilical cord 
blood, Wharton’s Jelly, and placenta19-21. Because 
these tissues are discarded after delivery, so they 
don’t put the newborn and the mother at risk.  
Researchers insist that Pancreas genesis and Neural 
System genesis have some similarities, although 
these two tissues were formed by different 
resources22-24.  
In this way, Pancreas endocrine cells are produced 
from embryonic stem cells using the a novel 
method  called “neuron production” as follow: : 1) 
genesis of embryonic body(EB) which includes the 
cells differentiating the three layer 2) differentiation 
of cells which express nestin against fetal bovine 
serum reduction and culturing in ITSFN(Insulin-
Transferrin-Selenium-Fibronectin), and 3) 
proliferation and maintaining precursor cells in the 
presence of alkaline fibroblastic growth 
factor(bFGF/FGF-2) in a medium free of serum, with 
N2, and B27 and 4) Induction of differentiation and 
maintaining positive insulin cells through adding 
Nicotine Amide and removing bFGF 25-27. 
Some researchers have shown that fibroblastic 
growth factors can play a significant role in 
differentiation of pancreatic B-cells in various 
dilutions. In this way, many FGFs, including 22 items 
have been examined. These factors are secreted 
from various tissues and affect the target tissue28.  
bFGF can stimulate angiogenesis in vitro and in vivo, 
and help diabetes treatment by angiogenesis. 
FGF10 play its role in signaling mesenchymal- 
epithelial interaction and cell proliferation.  
Other researchers have argued that the presence of 
neuro-epithelial protein nestin in human and rat 
islets Langerhans may by an indicator for endocrine 
precursor cells. Also, they showed that nestin is 
present in endothelial and mesenchymal cells of 
vessels inside and outside the islets of Langerhans, 
and showed that the cells proliferated in mature 
islets Langerhans are primarily endocrine29-32. 
Wang and Phuc et al. (2011) could create pancreatic 
β-cells from mesenchymal stem cells of umbilical 
cord blood, which, after injection, could lower 
blood glucose of diabetic rat.  
They found that mesenchymal stem cells of 
umbilical cord vein wall have less capacity in terms 
of differentiation, compared to Wharton’s Jelly 
mesenchymal cells and umbilical cord blood. Lower 
differentiation capacity is obvious in bone and fat 
differentiation33,34. 
Another research (2010) showed that growth 
factors, including retinoic acid, FGF and activin are 
used for differentiation of stem cells into cells which 
express PDX-135. 
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Until now, many researches have tried to produce 
mesenchymal stem cells and their differentiation 
into pancreatic β-cells using various molecules; 
unfortunately, they couldn’t produce prefect 
pancreatic β- cells.  
This research aims at isolation mesenchymal stem 
cells from Wharton’s Jelly. The differentiation of 
MSCs to pancreatic cells was evaluated in presence 
of ActivinA, Retinoic Acid, Fibroblast Growth 
Factor10, Nestin and Forskolin in culture medium. 
The concentration of the components, mentioned 
above, was also optimized in the culture. Thus, a 
novel method for producing pancreatic cells may be 
explained.   
 
MATERIALS AND METHODS 
Collection of human umbilical cord  
In an experimental study, human umbilical cord 
samples were collected in fully sterilized condition 
from six mothers after delivery at the Obstetrical 
Department of Imam Educational and Therapeutic 
Hospital, Sari, North of Iran. Then samples were 
transported to the Medical University.  
 
Preparation and culture of Wharton’s jelly  
First, in a 10 mm-plate, all clots and arteries of 
umbilical cord were isolated under laminar hood. 
Then, the gelatinous substance within the umbilical 
cord, Wharton jelly, was cut into small pieces 
mechanically, and was rinsed several times with 
Phosphorous buffered saline (PBS) at 1250 rpm for 
5 min. For lysing the remaining RBC, 2 ml 
Hypertonic Chloride, Ammonium (USA, Pharmin 
Gen) was added to the sample and was rinsed after 
10 min. Cell deposition, which included cells that 
separated from the placenta tissue, was transferred 
to T75 Flask and was cultured in High Glucose-
Dulbecco's Modified Eagle Medium- F12 (HG- 
DMEM-F12) (USA, Gibco) supplemented with 10 % 
fetal bovine serum (FBS) and 50 u/ml Penicillin-
Streptomycin. The plate was incubated in 5% CO2 at 
37 ºC.  
 
Isolation and characterization of Mesenchymal 
Stem Cells (MSCs) from other umbilical cord cells 
The medium was changed after 24 hours; the 
suspended particles (non-mesenchymal cells) 
migrated from the medium and the mesenchymal 
cells adhered to flask, and turned into spindle-like 
shapes. When the confluency of the cells reached 
80-90%, the mesenchymal cells were harvested 
using 0.25% trypsine including 1ml/M EDTA (USA, 
Sigma).  
The suspension was centrifuged at 1250 rpm for 5 
min. The cell deposition was rinsed two times and 
centrifuged. Finally, it was filtered using grade 70 
micron filter.  
To approve MSCs identity, positive markers of stem 
cell surface such as CD105, CD90, CD44 and 
negative markers, CD34 and HLA-DR were evaluated 
by flow cytometry.  Conjugating related antibodies, 
Fluor chromes FITC, PE and PerCP, isotype controls 
of PerCP, PE and IgG1-FITC were used.  
The WJ-MSCs were induced to differentiate into 
adipocytes, osteocytes and chondrocytes. The 
differentiation protocol has been described 
previously26. In this way, WJ-MSCs at 1.6 × 105 
cells/ml were cultured in HG-DMEM-F12 
complemented with 15% FBS and 2mMol/ L- 
glutamine and Penicillin-Streptomycin for 6 days. 
The cells were then fixed with 0.4% 
paraformaldehyde (PFA) and stained with oil-red-o 
(sigma) to confirm the adipocyte. For osteoblastic 
differentiation, the WJ-MSCs were cultured in HG-
DMEM-F12 complemented with 10 nMol/L b-
glycerol phosphate (sigma) and 50mg/ml ascorbic 
acid-2 phosphate (sigma). After fixation, the 
differentiated cells were stained with Alizarin red, 
and then the calcium deposition was confirmed. For 
chondrogenesis differentiation, WJ-MSCs were 
seeded in a HG-DMEM-F12 complete culture media 
at 1.6 × 105 cells/ml with 5 μl of chondrogenesis 
culture media for 14 days. The micromass cultures 
were then stained with Alcian blue. 
 
Differentiation of MSCs into insulin-producing cells  
After isolation and confirmation of MSCs, 
optimization of Activin A, Retinoic Acid, Fibroblast 
Growth Factor10, Nestin and Forskolin in various 
dilutions were checked in the culture, and the 
optimum dilution was obtained. Then induction 
treatment was conducted in 3-5 days. Stimulating 
cell proliferation, various additives, including 
(Gibco) B27 and (Gibco) N2 were added to the 
culture.  
 








To examine the morphology of differentiated cells, 
they were stained with Dithizone by completely 
dissolving 50 mg of DTZ (Sigma) in 5 ml of dimethyl 
sulfoxide (DMSO, Sigma). The solution was stored in 
-20 ᵒC in the dark. At the time of staining, the 
working solution was prepared by diluting the stock 
solution (pH 7.8) to a ratio of 1:100 in the culture 
medium. We added 3 ml of the working DTZ 
solution to each well and the plates were incubated 
for 30 min at 37ᵒC. The plates were then rinsed 
three times with PBS and crimson-red differentiated 
clusters were examined with an inverted phase 
contrast microscope. 
 
Enzyme-linked immunosorbent assay (ELISA) 
For evaluation of insulin secretion, the supernatant 
of differentiated cells was collected and insulin 
content was examined by ELISA method using an 
Insulin ELISA kit (Demeditec, Germany) according to 
the protocol. 
The evaluation of the PDX-1 expression in mRNA 
level which confirms the insulin-producing cells was 
done by reveres transcription polymerase chain 
reaction (RT-PCR). 
 
RNA extraction and cDNA synthesis  
Extraction of total RNA from differentiated cells was 
used by AccuzolTM, a ready-to-use reagent (Bioneer, 
Korea) according to the manufacturer’s protocol. 
After evaluating the quality and quantity of RNA by 
electrophoresis and spectrophotometer, 
respectively, cDNA synthesis was done by 
AccuPower® CycleScript RT Premix (dN6) (Bioneer, 
Korea). The concentration of RNA used for cDNA 
synthesis was 1µg. The thermal profile for cDNA 
synthesis was: primer annealing at 25℃ for 30 s, 
cDNA synthesis at 45 ℃ for 4 min and melting 
secondary structure & cDNA synthesis at 55℃ for 
30 s and repeated 12 times as well as heat 
inactivation at 95℃ for 5 min. 
 
Reverse transcription polymerase chain reaction 
(RT-PCR) 
For assessment of insulin-producing cells, we 
evaluated expression of PDX-1 gene, which was 
related to insulin production. First, to set the 
primers, we performed conventional PCR. PCR 
amplification was done for PDX-1 gene and EF-1 as 
reference gene, in a Thermocycler (Eppendorf, UK) 
by using 2μl of CDNA, 1μM of each primer, and 
12.5μl of Taq DNA Polymerase 2x Master Mix, Red 
(Ampliqon, Denmark) in a 20 µl total volume 
reaction.  
The primer sequences were as follows: EF1 
(Forward): 5´-CTGAACCATCCAGGCCAAAT-3´ and 
EF1 (Reverse):  5´-GCCGTGTGGCAATCCAAT-3´ which 
amplified a 59 bp fragment and for PDX1 gene we 
used GGATGAAGTCTACCAAAGC-3´ as a forward and 
5´-CGTGAGATGTACTTGTTGAA-3´ as reverse to 
amplify a 157 bp fragment. The thermal profile for 
amplification were 95ᵒC for 2 min for initial 
denaturation, followed by 40 cycles denaturation at 
95ᵒC for 30s, annealing at 45ᵒC  for EF-1 and 56ᵒC 
for PDX-1 for 30s, extension at 72ᵒC for 30S, and 
final extension at 72ᵒC for 2 min.  
PCR products were electrophoresed on 2% agarose 
gel. Electrophoresis was performed at 100v for 40 
min. Fragments with 59 bp and 157 bp were scored 
as EF1 and PDX1 gene, respectively.  
 
Real-time polymerase chain reaction (RT-PCR) 
Evaluation of PDX1 expression at mRNA level was 
performed using the real-time PCR system (IQ5, 
Biorad, USA). The EF1 gene was used as an 
endogenous reference gene allowing normalization 
of the expression level of the target gene to 
normalize the expression levels of target gene. 
Primer sequence was mentioned in RT-PCR part. We 
used SYBR Premix EX TaqII (2X) (Takara, Cat. #: 
RR820L) master mix for amplification. The thermal 
profile for PDX-1 and EF-1 were as follows: The 
thermal profile was as follows: Initial denaturation 
at 95°C for 2 min, followed by 45 cycles of 
denaturation at 95°C for 30 s, primer annealing for 
PDX-1 at 56°C and for EF-1 at 45°C for 30 s, and 
extension at 72°C for 30 s. This cycle was followed 
by a melting curve analysis, ranging from 45°C for 
EF-1 and 56°C for PDX-1 to 95°C, with increasing 
steps in temperature ( 0.5°C every 10 s).  
 
Statistical analysis 
The relative expression of PDX-1 was calculated by 
2-ΔΔCt, as previously described by Livak36.The data 
were presented as means ± SD. Data were assessed 
by one-way ANOVA followed by Tukey’s test for 
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comparison of the experimental group. The 
statistical analysis was performed using SAS 
software. P-values <0.05 were considered 
statistically significant (Figure 6). 
 
 
Figure 6. PD X-1 gene expression in MSCs and IPCs 
P-value = 0.001 
RESULTS 
   In our study, we differentiated Wharton jelly´s 
mesenchymal stem cells (WJ-MSCs) toward insulin-
producing cells (IPCs). For this purpose, after 
isolation and differentiation of WJ-MSCs toward 
IPCs, we performed the morphological and 
molecular analysis.  
 
Morphological and Phenotypical Characterization 
of WJ-MSCs 
At the end of the expansion phase, the cultured WJ-
MSCs become homogenous, spindle shaped, and 









Figure 1. The Wharton`s Jelly mesenchymal cells were grown from from 
the edge of tissue explants and homogenous population of fibroblast-
like MSCs at passage 2 (× 100)        
 
Flow cytometric analysis showed that these cells 
expressed high levels of CD90, CD105 and CD44, but 
negligible levels of CD34, and HLA-DR, which are 
surface markers for hematopoietic stem cells. 
Moreover, their multilineage differentiation 
potential was confirmed. The cells have the 
potential to differentiate into adipocytes, 
chondrocytes, and osteocytes when they were 
exposed the appropriate growth factors. These data 
indicate that MSCs were the majority of the WJ-
derived cells.   
 
Dithizone (DTZ) staining 
In order to evaluate insulin production in clusters at 
day 21 of differentiation, we used dithizone (DTZ) 
staining. The stock solution was prepared as 
previously described37. Insulin-producing cells are 
























Figure 2. DTZ (Dithizone) staining; observed with inverted 
microscope and magnified ×100 ; A: Untreated cells, B: In cells 
treated with dithizone, insulin granules come in red brick. 
 
ELISA test  
In order to determine the amount of insulin 
secreted by the differentiated cells after the day 28, 
the cell culture medium was tested by using ELISA 
technique. The results showed that the 
differentiated cells compared to the 
undifferentiated cells, secrete insulin. We could be 
able to differentiate MSCs toward the insulin 
producing cells. 
 
PDX-1 expression in IPCs 
After differentiation, the expression of β-cell 
specific gene such as PDX-1 was assessed in 
Wharton jelly mesenchymal stem cell and insulin-
producing cells by qRT-PCR. The results of RT-PCR 
for primers assessment are shown in Figure 3. The 
amplification plot and melt curve of PDX-1 and EF-1 
represent in Figures 4-a,b and 5-a,b, respectively. 
The expression levels of PDX1 versus EF1 in IPCs 
were7.55 fold-changes higher than WJ-MSCs, and it 












Figure 3. Electrophoresis of PDX-1 and EF-1 on 2% agarose gel; 
M shows marker (100bp); Lane 1, 2 represent PCR product of the EF-1 
amplification in 45ᵒC; Lane 3, 4 represent PCR product of the PDX-1 











Hossein Ranjbaran, et al.                                                                     IJHOSCR, 1 July. Volume 12, Number 3 
226 
 
 International Journal of Hematology Oncology and Stem Cell Research 
ijhoscr.tums.ac.ir  
 







Figure 5. Amplification plot (a) and melt curve (b) of PDX-1Gene 
 
DISCUSSION  
   MSCs are self-renewing cells with multilineage 
differentiation potential38. The ease of isolation and 
expansion has rendered any potentially significant 
source of stem cells as it could be used in the tissue 
engineering and regenerative medicine, whereas it 
represents a therapeutic potential for DM33. 
Previously, some publications demonstrated the 
differentiation capability of adult stem cells toward 
the pancreatic cell lineage39-43. Recent studies have 
revealed the potential of MSCs from different 
sources for the treatment of the diabetes mellitus 
44,45 and the diabetic complications, including 
diabetic cardiomyopathy46, diabetic retinopathy47, 
diabetic polyneuropathy48, diabetic nephropathy49 
and diabetic wounds50. MSCs can be isolated from 
several organs and tissues, e.g. bone marrow, 
dental pulp, adipose tissues, and umbilical cords51. 
Wharton`s Jelly method was used to derive MSCs, 
by which several significant advantages have been 
reflected such as the high number and the relatively 
easy isolation52. MSCs are capable to differentiate 
into islet-like cells and it has immunomodulatory 
abilities subject to the possibility to reduce the risk 
of immune rejection53. Insulin Producing Cells (IPCs) 
can be obtained by two methods: indirect and 
direct differentiation. The indirect differentiation 
application for the chemicals, for example, 
nicotinamide and growth factors are shown as 
inductors. In this method, the application of the 
high glucose concentration in the medium is critical, 
since it is a potent inducer of differentiation. 
Another method is direct differentiation, which is 
based on the modification of the genetic material, 
for example, by using the viral vectors54. 
Raikwar et al. (2013) reported the ectopic 
expression of Pancreatic and duodenal home box 
Factor-1(PDX-1) which is a critical transcription 
factor for pancreas, and increased embryonic stem 
cells differentiation into insulin producing cells.  
Sipione and Hanson and Rajagopal et al. (2003-
2004) tried to show that transplanted stem cells 
promote treatment of diabetes. They, in their 
research, reported that neurons and neural 
precursors are the main producers of 
insulin/proinsulin 55-57. 
Moreover, in a study which yielded 7.3u/ml insulin, 
endodermal layer cells were sustained using Activin 
A and then adding FGF10 and retinoic acid  led to 
PDX-1 cells expression as the main marker of the 
insulin producing  cells58-59.  
In other study, researchers showed that 
endodermal cells can generate pancreatic 
precursors in exposure of Retinoic acid and 
cyclopamin60, 61.  
One of the important signs of the beta pancreatic 
cells is the insulin secretion. Thereby, in the present 
study, the secretion rate of insulin in the 
differentiated MSCs was studied. 
In this research, after the successful isolation of 
mesenchymal stem cells (MSCs) and its 
confirmation via three approaches, including 
adhesion of fibroblast spindle-shaped cells at the 
bottom of the flask and the differentiation into the 
fat, bone and cartilage cell lines and the 
examination of the positive and negative CD 
markers, in the next phase, we conducted the 
differentiation into the pancreatic β cells with 
Activin A (100 ng/ml), Retinoic Acid (0.2 nM/ml), 
Fibroblast Growth Factor10 (20 ng/ml), Nestin (50 
ng/ml) and Forskolin (250 ng/ml) and optimized 
their concentration in the various dilutions in the 
culture medium, where we could produce the 
insulin producing cells.  
In this study, mesenchymal stem cells (MSCs) were 
differentiated into the pancreatic β cells with 
Activin A, Retinoic Acid, Fibroblast Growth Factor10, 
Nestin and Forskolin and optimized their 
concentration in the various dilutions in the culture 
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medium, where we could produce adequate the 
insulin secreting cells. In our study, the best 
molecular combination to produce insulin was 
Forskolin+Activin A+ Fibroblast Growth Factor10 
and Retinoic Acid (211/7u/ml), as it was determined 
by ELISA. 
It is required to study the combination of the 
differentiate factors mentioned above in the animal 
model. In respect to the efficient role of the in vivo 
compared to the in vitro on the differentiation, the 
study of this subject seems indispensable. 
 
CONCLUSION 
   Mesenchymal stem cells were differentiated into 
the pancreatic β cells with Activin A, Retinoic Acid, 
Fibroblast Growth Factor10, Nestin and Forskolin 
and optimized their concentration in the various 
dilutions in the culture medium. We optimized the 
best molecular combination to produce adequate 
insulin level. Therefore, it is concluded that MSCs 
may be considered as an excellent candidate in β- 
cell therapy in diabetes patients. 
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